+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enzalutamide Soft Capsules Market - Global Forecast 2025-2030- Product Image
Enzalutamide Soft Capsules Market - Global Forecast 2025-2030- Product Image
Sale

Enzalutamide Soft Capsules Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6125986
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The enzalutamide soft capsule market is entering a pivotal phase as advancements in oncology, regulatory policy, and patient-centered care converge. Senior decision-makers are navigating an increasingly complex ecosystem, where innovative dosage forms, evolving treatment guidelines, and global supply complexities are fundamentally redefining market strategy and stakeholder engagement.

Enzalutamide Soft Capsule Market Snapshot

The enzalutamide soft capsule market is characterized by robust clinical adoption, propelled by modern androgen receptor inhibition technologies and improved patient adherence rates. The segment is buoyed by a growing emphasis on personalized therapy and quality of life, with soft capsule formulations becoming integral across metastatic and non-metastatic prostate cancer care pathways. Notably, the market benefits from a convergence of regulatory endorsements and shifts in reimbursement, facilitating greater access for a wider spectrum of patients. The region-specific regulatory, payer, and procurement environments create varied entry barriers and opportunities for manufacturers and distributors.

Scope & Segmentation of the Enzalutamide Capsules Market

This report provides a comprehensive analysis of the enzalutamide capsules sector, underpinned by in-depth segmentation and global coverage.

  • Indications: Covers metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer, further segmented by first, second, and third-line therapies.
  • Dosage Strengths: Profiles 40 mg, 80 mg, and 120 mg options, offered in both blister packs and bottles.
  • Distribution Channels: Assesses private and public hospital pharmacies, online platforms (direct-to-consumer, third-party), and retail pharmacies (chain and independent).
  • End Users: Details utilization across general and specialty clinics, private and public hospitals, cancer research institutes, and specialist oncology centers.
  • Purchase Types: Distinguishes between new prescriptions and refill patterns—both complete and partial.
  • Regional Analysis: Maps market dynamics in the Americas (including United States, Canada, and Latin America), Europe, Middle East, Africa, and Asia-Pacific. Key markets range from the United States and major European economies to high-growth Asia-Pacific territories.
  • Companies Profiled: Strategic reviews for industry leaders such as Astellas Pharma Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Viatris Inc., Dr. Reddy’s Laboratories Limited, Cipla Limited, Sun Pharmaceutical Industries Limited, Lupin Limited, and Glenmark Pharmaceuticals Limited.

Key Takeaways: Strategic Insights for Decision-Makers

  • Next-generation androgen receptor inhibitors in soft capsule form address resistant disease proficiencies and fit the growing trend toward personalized patient care.
  • Evolving guidelines and regulatory convergence are positioning enzalutamide soft capsules as pivotal in multiple therapy lines, supporting expanded use cases and payer acceptance.
  • Companion diagnostics and genomic profiling are refining patient stratification, while digital patient support platforms foster greater adherence, leading to continuity in real-world settings.
  • Emergence of biosimilar entrants and innovative partnership models is intensifying competition, prompting originators and generics to invest in value-based healthcare collaborations.
  • Regional heterogeneity across reimbursement and regulatory frameworks necessitates flexible channel and pricing strategies to unlock market potential and mitigate risks.
  • Multi-faceted distribution and tailored services—from specialized hospital networks to online pharmacies—optimize patient reach and align with diverse procurement cycles.

Tariff Impact on Enzalutamide Capsule Supply Chains

Recent United States tariff adjustments have introduced significant cost pressures on both active pharmaceutical ingredients and packaging materials relevant to enzalutamide soft capsules. Manufacturers are actively adapting by revisiting global sourcing, exploring near-shoring, and diversifying suppliers to manage input costs and safeguard supply continuity. Downstream, these shifts prompt new negotiations for distributor terms and pharmacy contracts. Simultaneously, trade exemptions and emerging free trade agreements are partially offsetting impacts, while partnerships with contract manufacturing organizations continue to drive flexibility and resilience.

Methodology & Data Sources

The research approach integrates peer-reviewed studies, regulatory filings, clinical trial databases, and expert interviews with oncologists, payers, and supply chain stakeholders. Both quantitative and qualitative data were triangulated. Rigorous coding and cross-verification processes, including peer review and data audit, underpin the validity and reliability of findings throughout this report.

Why This Report Matters to Industry Leaders

  • Provides actionable, segment-specific insights to inform market expansion, product positioning, and stakeholder engagement initiatives.
  • Equips decision-makers with timely analysis of supply chain vulnerabilities, tariff impacts, and payer dynamics across priority regions.
  • Enables strategic alignment around emerging patient needs, technology platforms, and regulatory shifts in the enzalutamide soft capsule sector.

Conclusion

Senior leaders leveraging this analysis will be well-equipped to navigate volatility in the enzalutamide capsule market. Success requires agile, evidence-based strategy spanning clinical, commercial, and regulatory domains.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising use of enzalutamide soft capsules in first-line treatment of metastatic castration-resistant prostate cancer
5.2. Expanding patient preference for oral enzalutamide soft capsules in advanced prostate cancer therapy
5.3. Impact of patent expiry and generic competition on enzalutamide soft capsule market dynamics
5.4. Strategic partnerships driving global distribution networks for enzalutamide soft capsules
5.5. Advancements in drug formulation technologies improving enzalutamide soft capsule bioavailability
5.6. Clinical trial outcomes influencing enzalutamide soft capsule indication expansion in nonmetastatic prostate cancer
5.7. Price negotiation and reimbursement policies shaping enzalutamide soft capsule market accessibility
5.8. Regional market growth patterns for enzalutamide soft capsules in Asia-Pacific and Latin America
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Enzalutamide Soft Capsules Market, by Indication
8.1. Introduction
8.2. Metastatic Castration-Resistant Prostate Cancer
8.2.1. First Line
8.2.2. Second Line
8.2.3. Third Line
8.3. Metastatic Hormone-Sensitive Prostate Cancer
8.3.1. First Line
8.3.2. Second Line
8.3.3. Third Line
8.4. Non-Metastatic Castration-Resistant Prostate Cancer
8.4.1. First Line
8.4.2. Second Line
8.4.3. Third Line
9. Enzalutamide Soft Capsules Market, by Dosage Strength
9.1. Introduction
9.2. 120 Mg
9.2.1. Blister Pack
9.2.2. Bottle
9.3. 40 Mg
9.3.1. Blister Pack
9.3.2. Bottle
9.4. 80 Mg
9.4.1. Blister Pack
9.4.2. Bottle
10. Enzalutamide Soft Capsules Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Private Hospital
10.2.2. Public Hospital
10.3. Online Pharmacy
10.3.1. Direct-To-Consumer
10.3.2. Third-Party Platform
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. Enzalutamide Soft Capsules Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. General Clinics
11.2.2. Specialty Clinics
11.3. Hospitals
11.3.1. Private Hospital
11.3.2. Public Hospital
11.4. Specialty Centers
11.4.1. Cancer Research Institutes
11.4.2. Oncology Centers
12. Enzalutamide Soft Capsules Market, by Purchase Type
12.1. Introduction
12.2. New Prescription
12.3. Refill
12.3.1. Complete Refill
12.3.2. Partial Refill
13. Americas Enzalutamide Soft Capsules Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Enzalutamide Soft Capsules Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Enzalutamide Soft Capsules Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Astellas Pharma Inc.
16.3.2. Pfizer Inc.
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.4. Sandoz International GmbH
16.3.5. Viatris Inc.
16.3.6. Dr. Reddy’s Laboratories Limited
16.3.7. Cipla Limited
16.3.8. Sun Pharmaceutical Industries Limited
16.3.9. Lupin Limited
16.3.10. Glenmark Pharmaceuticals Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ENZALUTAMIDE SOFT CAPSULES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ENZALUTAMIDE SOFT CAPSULES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ENZALUTAMIDE SOFT CAPSULES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ENZALUTAMIDE SOFT CAPSULES MARKET: RESEARCHAI
FIGURE 26. ENZALUTAMIDE SOFT CAPSULES MARKET: RESEARCHSTATISTICS
FIGURE 27. ENZALUTAMIDE SOFT CAPSULES MARKET: RESEARCHCONTACTS
FIGURE 28. ENZALUTAMIDE SOFT CAPSULES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ENZALUTAMIDE SOFT CAPSULES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BLISTER PACK, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BOTTLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BOTTLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BLISTER PACK, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BOTTLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BOTTLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BLISTER PACK, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BOTTLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY BOTTLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COMPLETE REFILL, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COMPLETE REFILL, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PARTIAL REFILL, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PARTIAL REFILL, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 207. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 210. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 211. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 212. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 213. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 214. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 215. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 216. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 217. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2018-2024 (USD MILLION)
TABLE 218. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2025-2030 (USD MILLION)
TABLE 219. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2018-2024 (USD MILLION)
TABLE 220. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2025-2030 (USD MILLION)
TABLE 221. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2018-2024 (USD MILLION)
TABLE 222. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2025-2030 (USD MILLION)
TABLE 223. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 226. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 227. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 230. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 231. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 234. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 235. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 236. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 237. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 238. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 239. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2024 (USD MILLION)
TABLE 240. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025-2030 (USD MILLION)
TABLE 241. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2018-2024 (USD MILLION)
TABLE 242. CANADA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2025-2030 (USD MILLION)
TABLE 243. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 246. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 247. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 248. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 249. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 250. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 251. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 252. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 253. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2018-2024 (USD MILLION)
TABLE 254. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2025-2030 (USD MILLION)
TABLE 255. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2018-2024 (USD MILLION)
TABLE 256. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2025-2030 (USD MILLION)
TABLE 257. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2018-2024 (USD MILLION)
TABLE 258. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2025-2030 (USD MILLION)
TABLE 259. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 262. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 263. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 274. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 275. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2024 (USD MILLION)
TABLE 276. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025-2030 (USD MILLION)
TABLE 277. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2018-2024 (USD MILLION)
TABLE 278. MEXICO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL ENZALUTAMIDE SOFT CAPSULES MARKET S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Enzalutamide Soft Capsules market report include:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Limited
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited

Related Topics

Related Reports

Enzalutamide Drugs Market - Global Forecast 2025-2030 - Product Image

Enzalutamide Drugs Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Enzalutamide Tablets Market - Global Forecast 2025-2030 - Product Image

Enzalutamide Tablets Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034 - Product Image

Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2025 - Product Image

Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.